AMAG Pharmaceuticals Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St bounces as oil cools, inflation risks keeps Fed in focus
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
AMAG Pharma (AMAG) Misses Q3 EPS by 16c; Boosts FY15 Outlook
November 3, 2015 7:33 AM ESTAMAG Pharma (NASDAQ: AMAG) reported Q3 EPS of $1.02, $0.16 worse than the analyst estimate of $1.18. Revenue for the quarter came in at $103.5 million versus the consensus estimate of $113.88 million.
AMAG Pharma sees FY2015 revenue of $425-450 million, versus prior guidance of $395-430 million and the... More
